Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06004947 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
A Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT06004947: Completed Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, sponsored by Amgen.
NCT06004947 is a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis that has completed, run by Amgen. The registered enrollment target is 32 participants, below the 108-participant average among 5 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06004947, a Phase 1 study of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Celecoxib
- DRUG Itraconazole
- DRUG Rifampicin
- DRUG CCX168
Study Locations (1)
Arizona
- Celerion - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2016-06-10 |
| Phase | Phase 1 |
What the finished NCT06004947 record still lists
NCT06004947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 108-participant average among 5 other Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis appearing as the primary indexed condition, and to 5 interventions - of which Midazolam is the first listed.
NCT06004947 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06004947 about?
NCT06004947 is a clinical study titled "A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications". The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy participants.
What is the current status of trial NCT06004947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-01-14. Estimated completion is 2016-06-10.
What conditions does trial NCT06004947 study?
This clinical trial studies the following conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT06004947?
The interventions under investigation include: Midazolam (DRUG), Celecoxib (DRUG), Itraconazole (DRUG), Rifampicin (DRUG), CCX168 (DRUG).
Who is sponsoring clinical trial NCT06004947?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06004947 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
RECRUITING · Phase 1
-
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
ACTIVE NOT RECRUITING · Phase 1
-
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 1
-
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
COMPLETED · Phase 1
-
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI